We selected a Trp53-driven model because mutations in TP53 occur frequently in breast cancer, are more common in BRCA1 or BRCA2 mutation carriers, and associate with aggressive tumors and adverse prognosis (Koboldt et al., 2012; Stunnenberg et al., 2016). The gene discussed is BRCA1; the disease is breast cancer.